Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes
Expert Review of Clinical Pharmacology · 2025
DOI: 10.1080/17512433.2025.2527092 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von A J Scheen. Beteiligte Einrichtung: Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
INTRODUCTION: Older adults with type 2 diabetes mellitus (T2DM) are increasingly numerous worldwide and present particularly difficult therapeutic challenges, especially concerning the proper selection of antidiabetic medications that offer the best efficacy/safety ratio in this age group. AREAS COVERED: This narrative review summarizes progress toward personalized management involving a three-step process. First, patients should be categorized according to their frailty status. Second, glycemic targets should be properly individualized considering a higher risk of severe hypoglycemia in older patients. Third, the selection of the best antidiabetic medication(s) in order to avoid hypoglycemia but also to offer cardiorenal protection. In this respect, sulfonylureas and insulin therapy are currently less recommended and newer antidiabetic medications are preferred, usually combined with metformin: DPP-4 inhibitors (gliptins) for their better safety profile versus sulfonylureas, GLP-1 analogues or SGLT2 inhibitors (gliflozins) if cardiorenal protection is required. Reducing excessive body weight appears less critical in older patients and sarcopenia should be avoided. EXPERT OPINION: The two most recognized challenges are undertreating healthy older patients while overtreating frailty/ill people. The increasing armamentarium to treat T2DM offers new opportunities to personalize the use of antidiabetic medications according to the clinical profile and need of every older patient with T2DM. Older adults with type 2 diabetes mellitus (T2DM) are increasingly numerous worldwide. This presents particularly difficult challenges, especially when selecting diabetes medications that offer the best balance of effectiveness and safety for this age group. One major difficulty is the wide variety among older people, who can be divided into healthy individuals, frail people, and ill patients. The two most recognized challenges doctors face are 1) undertreating healthy older patients and 2) overtreating frail or ill people. One key goal is to avoid low blood sugar (hypoglycemia), which occurs more frequently and can be more dangerous in older patients than younger ones. Another goal is to identify older people with atherosclerotic cardiovascular disease, heart failure and/or chronic kidney disease and to offer them modern medications that have, in the last decade, been proven to protect both heart and kidney function. The growing selection of medications available to treat T2DM offers new opportunities to personalize the use of antidiabetic medications according to each older patient’s specific health profile and needs. Finding the right approach remains a challenging task in daily medical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium.
- Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium.
ORCID-Profile: A J Scheen
Zitieren
APA
Scheen, A. J. (2025). Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2527092
Vancouver
Scheen AJ. Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2527092
BibTeX
@article{Scheen2025,
author = {Scheen, A J},
title = {Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
doi = {10.1080/17512433.2025.2527092}
}
EUVIMED